pharmaphorum January 25, 2022
Canadian firm BenchSci has secured around $50 million in third-round financing that will be used to speed up the adoption of its artificial intelligence-powered platform for biomedical research internationally.
The Toronto-based company already counts many of the world’s largest pharma companies among its customers, using its platform for a range of tasks such as improving reagent and antibody selection to help scientists run more successful experiments, drawing on data from published studies and organisations’ internal databases.
The cash injection will “expedite the expansion” of the BenchSci platform, which it says is already used by around 49,000 scientists at more than 4,500 research centres worldwide, including 16 of the top 20 pharma companies.
The company is tapping into longstanding concerns in...
Today's Sponsors
Today's Sponsor